This Oral GLP-1 Pill Could Hit the Market Ahead of Schedule
Today, we’re diving into a hot topic following recent developments: the promising GLP-1 medication, Orforglipron. Eli Lilly just released Phase 3 trial data demonstrating positive efficacy and safety results .
What exactly is Orforglipron?
Orforglipron is a once daily, oral GLP-1 receptor agonist. Unlike typical GLP-1 drugs, which are large molecules, Orforglipron is a small molecule. This structural difference is thought to enhance its absorption within the body, enabling it to be taken orally and offering increased convenience compared to injectable GLP-1s.
What's the latest research saying?
Recent Phase 3 trial results (ACHIEVE-1), released this month, have been very encouraging. They showed significant reductions in HbA1c levels by 1.3% to 1.6% compared to placebo. Participants on the highest dose (36 mg) lost an average of approximately 16 pounds (7.3 kg), representing about 7.9% of their body weight after 40 weeks. This weight loss is comparable to Novo Nordisk’s Ozempic injections but slightly lower than Eli Lilly’s own injectable GLP-1 therapy, Zepbound. As with other GLP-1 medications, side effects primarily involved mild to moderate gastrointestinal issues, including nausea and diarrhoea.
Why is this important?
The introduction of Orforglipron could change how we approach obesity and type 2 diabetes management. Compared to weekly injections, its ease of use and cost effectiveness may improve patient adherence and satisfaction. This could, in turn, broaden the patient base for GLP-1 therapies.
When will it be available?
Eli Lilly plans to submit Orforglipron for weight management approval later this year and expects to submit for type 2 diabetes approval in 2026. Analysts anticipate availability in the US by the second half of next year if the FDA review goes smoothly.
How much will it cost?
Pricing isn't confirmed yet, but US industry experts predict a monthly sticker price just under $1,000, potentially lower than current injectables like Wegovy. Real world costs to patients will likely be lower, considering insurance coverage and patient assistance programs. It's worth mentioning that pricing outside the US is expected to be significantly less.
What more can we expect to learn?
Additional studies involving over 10,000 patients are underway, exploring Orforglipron's effectiveness in broader populations, including those with concurrent obesity, diabetes, cardiovascular disease, and sleep apnoea. More detailed data will be presented at upcoming medical conferences and published in peer reviewed journals throughout this year and next.
What's the impact for dietitians?
As dietitians, this is an exciting opportunity to re evaluate patient education and management strategies around GLP-1 therapies. Easier adherence and potentially fewer barriers to treatment initiation mean that nutritional counselling and lifestyle support could play even more significant roles in patient success. Preparing now by staying updated on this emerging therapy will empower us to best support our patients when Orforglipron hits the market.
References
Melson, E., Ashraf, U., Papamargaritis, D. et al. What is the pipeline for future medications for obesity?. Int J Obes 49, 433–451 (2025). https://doi.org/10.1038/s41366-024-01473-y
Eli Lilly and Company. (2024, April 22). Lilly’s oral GLP-1, orforglipron, demonstrated statistically significant and clinically meaningful reductions in A1C and body weight in adults with type 2 diabetes.
Thanks for reading!
Leif
Got feedback? Email leif@glp1dietitianhub.com, I'd love to hear from you.
Note: This newsletter is for educational purposes only and should not be considered medical advice. Always consult a qualified healthcare professional for personalised guidance.
Subscribe for free to receive new posts and support my work